Skip to main content

Advertisement

SpringerLink
Log in

Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.

Aim

We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC.

Material and method

Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis.

Results

A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression-free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05).

Conclusion

This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740–801

    PubMed  CAS  Google Scholar 

  2. Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer: is it becoming a reality? Nat Rev Clin Oncol 7:401–414

    Article  PubMed  CAS  Google Scholar 

  3. Singh N, Bal A, Aggarwal AN et al (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncol 6:741–767

    Article  PubMed  CAS  Google Scholar 

  4. Socinski MA (2010) The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin Lung Cancer 11:149–159

    Article  PubMed  CAS  Google Scholar 

  5. Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565–577

    Article  PubMed  CAS  Google Scholar 

  6. Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318–1328

    Article  PubMed  CAS  Google Scholar 

  7. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14:959–970

    PubMed  CAS  Google Scholar 

  8. Vogel U, Dybdahl M, Frentz G, Nexo BA (2000) DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197–210

    PubMed  CAS  Google Scholar 

  9. Vilmar A, Sørensen JB (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64:131–139

    Article  PubMed  Google Scholar 

  10. Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13:284–289

    Article  PubMed  CAS  Google Scholar 

  11. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Article  PubMed  CAS  Google Scholar 

  12. Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232

    PubMed  CAS  Google Scholar 

  13. Ren S, Zhou S, Zhang L et al (2010) High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 28:1078–1083

    Article  PubMed  CAS  Google Scholar 

  14. Andressoo JO, Hoeijmakers JH, de Waard H (2006) Nucleotide excision repair and its connection with cancer and ageing. Adv Exp Med Biol 570:45–83

    Article  Google Scholar 

  15. Hwang IG, Ahn MJ, Park BB et al (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386

    Article  PubMed  CAS  Google Scholar 

  16. Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377–384

    Article  PubMed  Google Scholar 

  17. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA (2010) Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights 5:9–20

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Uludag University Medical School, Bursa, Turkey

    Erdem Cubukcu, Omer Fatıh Olmez, Ozkan Kanat, Ender Kurt, Turkkan Evrensel & Osman Manavoglu

  2. Department of Pathology, Uludag University Medical School, Bursa, Turkey

    Ozlem Saraydaroglu

  3. Department of Internal Medicine, Uludag University Medical School, Bursa, Turkey

    Unsal Akcalı

Authors
  1. Erdem Cubukcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omer Fatıh Olmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozlem Saraydaroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Unsal Akcalı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ozkan Kanat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ender Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Turkkan Evrensel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Osman Manavoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erdem Cubukcu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cubukcu, E., Olmez, O.F., Saraydaroglu, O. et al. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome. Clin Transl Oncol 13, 826–830 (2011). https://doi.org/10.1007/s12094-011-0741-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0741-7

Keywords

Search

Navigation